From Genetic Risk Variant Discovery to Functional Validation in Autoimmune Diseases

From Genetic Risk Variant Discovery to Functional Validation in Autoimmune Diseases

by Arima Genomics

Life & Natural Systems Medicine & Health MFPre-clinical medicine: basic sciencesMFNMedical genetics
🎙 Arima Genomics 👥 1K 📅 August 4, 2022 ⏱ 51 min 👁 887 📄 webinar 🧭 2026-08-18
Available in: English (current) Français

Keywords

Hi-Cchromatin loopssystemic sclerosiscausal genesenhancers

Summary

The webinar, hosted by Arima Genomics, introduces 3D genomics and its applications in human health, particularly in cancer and autoimmune diseases. Kristin, a senior scientist, explains the concept of 3D genomics, highlighting how DNA is organized in the nucleus and how this organization affects gene regulation. She presents a case study from a Nature Genetics paper on T-cell acute lymphoblastic leukemia, where 3D genomics revealed a structural variant bringing an enhancer into proximity with the MYC oncogene, leading to aberrant expression. She also discusses a pan-cancer benchmarking study using FFPE samples, including a pediatric glioma case where Hi-C identified a novel structural variant near PD-L1, enabling successful immunotherapy. Dr. Gisela Orozco then focuses on autoimmune diseases, explaining how GWAS have identified risk variants, mostly in non-coding regions, and how functional genomics techniques like ATAC-seq, ChIP-seq, and Hi-C can link these variants to causal genes. She presents a study in systemic sclerosis using promoter capture Hi-C on CD4+ T cells and CD14+ monocytes from patients and controls, identifying cell-type-specific interactions and potential causal genes like IRF8 and STAT4, and a novel candidate gene NABP1. The webinar concludes with the importance of using disease-relevant primary cells and the potential of 3D genomics for drug target discovery.

204 words

Critical Evaluation

Value of the Information & Strength of the Argument

The webinar provides valuable insights into the application of 3D genomics for understanding disease mechanisms. It effectively demonstrates the utility of Hi-C in identifying structural variants and linking non-coding risk variants to target genes. The argumentation is solid, supported by published research and a compelling clinical case. The presentation is clear and logical, progressing from basic concepts to specific examples. However, it is somewhat promotional for Arima’s technology, which may introduce bias. The scientific content is accurate and up-to-date, but the focus on Arima’s products limits the breadth of discussion.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, with references to a peer-reviewed publication (Kloetgen et al., 2020) and a clinical case from NYU Langone. The sources are credible, but the webinar does not provide a comprehensive list of references, and the promotional nature may affect objectivity. The title accurately reflects the content, which covers the entire pipeline from risk variant discovery to functional validation. The webinar is well-structured and technically sound, but the lack of external sources and the commercial context slightly reduce the overall rigor.

189 words

Title / Content Match

The title accurately reflects the content, which covers the journey from GWAS risk variant discovery to functional validation using 3D genomics in autoimmune diseases.

Quality & Reliability

8/10

The webinar is presented by a scientist from Arima Genomics, a company specializing in 3D genomics, and includes a detailed case study from a peer-reviewed publication (Kloetgen et al., 2020) and a clinical case from NYU Langone. The content is technically accurate and well-structured, but it is promotional in nature, which slightly reduces the objectivity score.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

  • Kloetgen et al., Nature Genetics 2020 — Paper on 3D genome in T-ALL, showing enhancer hijacking of MYC.
  • Arima Genomics — Company website for Hi-C kits and services.

Concurring Sources

  • Kloetgen et al., Nature Genetics 2020 — Supports the use of 3D genomics in cancer.
  • Arima Genomics — Company providing Hi-C technology.

Contribution & Novelties

The webinar provides a clear demonstration of how 3D genomics can bridge the gap between GWAS risk variants and causal genes, particularly in autoimmune diseases. The novelty lies in the application of promoter capture Hi-C to primary cells from patients, revealing cell-type-specific interactions that are crucial for interpreting disease-associated variants. The case of NABP1 as a potential novel causal gene in systemic sclerosis highlights the power of this approach to uncover previously unconsidered genes.

Pour aller plus loin :

  • Hi-C — Overview of Hi-C technology.
  • GWAS — Explanation of genome-wide association studies.
  • Enhancer (genetics) — Role of enhancers in gene regulation.

101 words

Radar Profile

The radar profile shows high scores in information quantity and quality, with moderate technical level and high reliability. This indicates a well-balanced webinar that is informative and credible, though it may require some background knowledge to fully appreciate.

Reliability 8/10

💬 No comments were provided for analysis.